| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperparathyroidism, Secondary | 31 | 2022 | 70 | 7.630 |
Why?
|
| Hyperphosphatemia | 19 | 2023 | 21 | 7.350 |
Why?
|
| Renal Insufficiency, Chronic | 31 | 2023 | 350 | 7.090 |
Why?
|
| Renal Dialysis | 47 | 2023 | 355 | 7.060 |
Why?
|
| Kidney Failure, Chronic | 41 | 2023 | 509 | 5.790 |
Why?
|
| Ferric Compounds | 14 | 2023 | 38 | 4.620 |
Why?
|
| Sucrose | 13 | 2023 | 64 | 4.500 |
Why?
|
| Parathyroid Hormone | 44 | 2020 | 218 | 4.480 |
Why?
|
| Phosphorus | 23 | 2023 | 118 | 3.930 |
Why?
|
| Ergocalciferols | 15 | 2020 | 38 | 3.470 |
Why?
|
| Vitamin D Deficiency | 11 | 2020 | 103 | 3.290 |
Why?
|
| Phosphates | 13 | 2023 | 160 | 3.210 |
Why?
|
| Vitamin D | 17 | 2020 | 261 | 3.160 |
Why?
|
| Chelating Agents | 11 | 2023 | 69 | 2.880 |
Why?
|
| Bone and Bones | 19 | 2015 | 265 | 2.820 |
Why?
|
| Chronic Kidney Disease-Mineral and Bone Disorder | 14 | 2019 | 23 | 2.590 |
Why?
|
| Kidney Diseases | 17 | 2010 | 418 | 2.580 |
Why?
|
| Bone Diseases, Metabolic | 9 | 2018 | 33 | 2.570 |
Why?
|
| Calcitriol | 15 | 2020 | 174 | 2.470 |
Why?
|
| Kidney Transplantation | 14 | 2020 | 849 | 2.460 |
Why?
|
| Calcium | 31 | 2016 | 1156 | 2.340 |
Why?
|
| Lanthanum | 7 | 2023 | 16 | 2.260 |
Why?
|
| Vitamins | 6 | 2016 | 81 | 2.050 |
Why?
|
| Bone Diseases | 7 | 2020 | 54 | 1.950 |
Why?
|
| Bone Density | 17 | 2018 | 209 | 1.660 |
Why?
|
| beta 2-Microglobulin | 11 | 2008 | 24 | 1.650 |
Why?
|
| Glomerular Filtration Rate | 14 | 2021 | 384 | 1.530 |
Why?
|
| Calcifediol | 4 | 2019 | 21 | 1.520 |
Why?
|
| Fibroblast Growth Factors | 7 | 2020 | 80 | 1.500 |
Why?
|
| Minerals | 3 | 2018 | 22 | 1.420 |
Why?
|
| Drug Combinations | 13 | 2023 | 224 | 1.310 |
Why?
|
| Humans | 133 | 2023 | 86601 | 1.230 |
Why?
|
| Sevelamer | 6 | 2020 | 6 | 1.150 |
Why?
|
| Amyloidosis | 8 | 2008 | 115 | 1.080 |
Why?
|
| Calciphylaxis | 2 | 2016 | 4 | 1.050 |
Why?
|
| Receptors, Calcitriol | 4 | 2016 | 129 | 0.950 |
Why?
|
| Osteoporosis | 7 | 2011 | 121 | 0.940 |
Why?
|
| Naphthalenes | 5 | 2010 | 45 | 0.930 |
Why?
|
| Calcimimetic Agents | 4 | 2020 | 5 | 0.900 |
Why?
|
| Middle Aged | 52 | 2021 | 25017 | 0.880 |
Why?
|
| Calcium Channel Agonists | 5 | 2007 | 13 | 0.850 |
Why?
|
| Aged | 41 | 2021 | 18402 | 0.820 |
Why?
|
| Isoquinolines | 1 | 2021 | 72 | 0.800 |
Why?
|
| Intestinal Absorption | 1 | 2021 | 124 | 0.790 |
Why?
|
| Male | 63 | 2021 | 40956 | 0.790 |
Why?
|
| Parathyroidectomy | 3 | 2022 | 78 | 0.770 |
Why?
|
| Peritoneal Dialysis | 6 | 2017 | 32 | 0.760 |
Why?
|
| Bone Resorption | 5 | 2008 | 41 | 0.760 |
Why?
|
| Kidney Cortex | 2 | 2019 | 33 | 0.730 |
Why?
|
| Fractures, Bone | 5 | 2007 | 131 | 0.710 |
Why?
|
| Female | 61 | 2021 | 44507 | 0.710 |
Why?
|
| Intestine, Small | 1 | 2021 | 303 | 0.700 |
Why?
|
| Polyamines | 3 | 2014 | 32 | 0.690 |
Why?
|
| Sulfonamides | 1 | 2021 | 300 | 0.690 |
Why?
|
| Bone Remodeling | 4 | 2023 | 24 | 0.670 |
Why?
|
| Treatment Outcome | 20 | 2019 | 7988 | 0.660 |
Why?
|
| Kidney Tubules | 1 | 2019 | 94 | 0.650 |
Why?
|
| Femoral Neck Fractures | 1 | 2018 | 11 | 0.640 |
Why?
|
| Chronic Disease | 12 | 2010 | 970 | 0.630 |
Why?
|
| Quality of Life | 3 | 2023 | 1583 | 0.620 |
Why?
|
| Fracture Fixation, Internal | 1 | 2018 | 66 | 0.610 |
Why?
|
| Biomarkers | 14 | 2023 | 1718 | 0.610 |
Why?
|
| Transplant Recipients | 1 | 2018 | 122 | 0.610 |
Why?
|
| Hypercalcemia | 5 | 2014 | 59 | 0.610 |
Why?
|
| Kidney | 9 | 2022 | 1241 | 0.590 |
Why?
|
| Hyperparathyroidism | 1 | 2016 | 67 | 0.580 |
Why?
|
| Aluminum | 12 | 1995 | 22 | 0.580 |
Why?
|
| Skull | 9 | 2008 | 249 | 0.570 |
Why?
|
| Bone Density Conservation Agents | 4 | 2016 | 45 | 0.550 |
Why?
|
| Adult | 36 | 2023 | 25640 | 0.540 |
Why?
|
| Nephrology | 1 | 2016 | 45 | 0.540 |
Why?
|
| Immunosuppressive Agents | 6 | 2020 | 977 | 0.540 |
Why?
|
| Disease Progression | 9 | 2021 | 1531 | 0.510 |
Why?
|
| Double-Blind Method | 10 | 2019 | 1823 | 0.510 |
Why?
|
| Iron | 4 | 2022 | 164 | 0.490 |
Why?
|
| Calcinosis | 3 | 2013 | 224 | 0.490 |
Why?
|
| Oxygen | 4 | 2021 | 726 | 0.480 |
Why?
|
| Skin Ulcer | 1 | 2013 | 25 | 0.470 |
Why?
|
| Osteoblasts | 4 | 2001 | 95 | 0.460 |
Why?
|
| Time Factors | 16 | 2021 | 5209 | 0.440 |
Why?
|
| Sodium Bicarbonate | 2 | 2023 | 10 | 0.430 |
Why?
|
| Osteoclasts | 4 | 2013 | 33 | 0.410 |
Why?
|
| Osteogenesis | 6 | 2017 | 242 | 0.410 |
Why?
|
| Glycation End Products, Advanced | 3 | 2013 | 13 | 0.400 |
Why?
|
| Calcification, Physiologic | 3 | 2007 | 33 | 0.390 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2011 | 54 | 0.390 |
Why?
|
| Pain | 1 | 2013 | 391 | 0.390 |
Why?
|
| Furosemide | 3 | 2019 | 33 | 0.380 |
Why?
|
| Risk Factors | 13 | 2015 | 5416 | 0.380 |
Why?
|
| Alkaline Phosphatase | 6 | 2015 | 132 | 0.370 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2021 | 3352 | 0.350 |
Why?
|
| Creatinine | 4 | 2021 | 338 | 0.350 |
Why?
|
| Oleanolic Acid | 2 | 2019 | 13 | 0.340 |
Why?
|
| Drug Interactions | 2 | 2021 | 248 | 0.330 |
Why?
|
| Cyclosporine | 3 | 2004 | 234 | 0.330 |
Why?
|
| Pancreas Transplantation | 3 | 2004 | 103 | 0.320 |
Why?
|
| Aged, 80 and over | 10 | 2019 | 6501 | 0.320 |
Why?
|
| Biopsy | 4 | 2009 | 1161 | 0.310 |
Why?
|
| Protein Kinase C | 2 | 1999 | 270 | 0.300 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2020 | 294 | 0.300 |
Why?
|
| Prognosis | 7 | 2018 | 3674 | 0.290 |
Why?
|
| Coronary Artery Disease | 1 | 2011 | 350 | 0.290 |
Why?
|
| Administration, Oral | 5 | 2020 | 684 | 0.290 |
Why?
|
| Retrospective Studies | 7 | 2023 | 8475 | 0.290 |
Why?
|
| Hip Fractures | 1 | 2007 | 45 | 0.290 |
Why?
|
| Metabolic Diseases | 1 | 2007 | 48 | 0.280 |
Why?
|
| Animals | 32 | 2021 | 26581 | 0.280 |
Why?
|
| Interleukin-6 | 3 | 2008 | 256 | 0.280 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 827 | 0.280 |
Why?
|
| Spinal Fractures | 1 | 2007 | 75 | 0.280 |
Why?
|
| Delayed-Action Preparations | 2 | 2016 | 116 | 0.270 |
Why?
|
| Severity of Illness Index | 6 | 2021 | 1801 | 0.260 |
Why?
|
| Prospective Studies | 8 | 2022 | 4210 | 0.240 |
Why?
|
| Canada | 3 | 2015 | 204 | 0.240 |
Why?
|
| Cross-Sectional Studies | 4 | 2021 | 1621 | 0.240 |
Why?
|
| Hospitalization | 2 | 2007 | 848 | 0.240 |
Why?
|
| Carbonates | 1 | 2023 | 5 | 0.240 |
Why?
|
| Azathioprine | 1 | 2004 | 125 | 0.230 |
Why?
|
| Biological Transport | 2 | 2021 | 396 | 0.220 |
Why?
|
| Tablets | 2 | 2023 | 118 | 0.220 |
Why?
|
| Medication Adherence | 3 | 2019 | 129 | 0.220 |
Why?
|
| Niacinamide | 2 | 2020 | 116 | 0.220 |
Why?
|
| Diabetic Nephropathies | 3 | 2019 | 248 | 0.220 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2011 | 2600 | 0.210 |
Why?
|
| Interleukin-1 | 2 | 2008 | 71 | 0.210 |
Why?
|
| Albuminuria | 2 | 2021 | 153 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 5 | 2019 | 1034 | 0.210 |
Why?
|
| Sodium-Hydrogen Exchanger 3 | 1 | 2021 | 32 | 0.210 |
Why?
|
| Glucose | 2 | 2002 | 638 | 0.200 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2007 | 1961 | 0.200 |
Why?
|
| Phosphorus, Dietary | 1 | 2020 | 4 | 0.190 |
Why?
|
| Iron Overload | 1 | 2020 | 6 | 0.190 |
Why?
|
| Kidney Medulla | 1 | 2021 | 80 | 0.190 |
Why?
|
| Diet | 2 | 2023 | 443 | 0.190 |
Why?
|
| Inflammation | 2 | 2020 | 920 | 0.190 |
Why?
|
| Cholecalciferol | 1 | 2020 | 35 | 0.190 |
Why?
|
| United States | 9 | 2022 | 6665 | 0.180 |
Why?
|
| Cognition Disorders | 2 | 1994 | 236 | 0.180 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2017 | 683 | 0.180 |
Why?
|
| Bone Substitutes | 1 | 1999 | 9 | 0.170 |
Why?
|
| Anemia | 1 | 2020 | 128 | 0.170 |
Why?
|
| Biomedical Engineering | 1 | 1999 | 20 | 0.170 |
Why?
|
| Mice | 13 | 2017 | 11352 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2019 | 1373 | 0.170 |
Why?
|
| Cytokines | 4 | 2012 | 776 | 0.170 |
Why?
|
| Bone Regeneration | 1 | 1999 | 52 | 0.170 |
Why?
|
| Absorbable Implants | 1 | 1999 | 34 | 0.170 |
Why?
|
| Waist Circumference | 1 | 2018 | 20 | 0.170 |
Why?
|
| Receptors, Immunologic | 2 | 2013 | 135 | 0.170 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2020 | 136 | 0.170 |
Why?
|
| Drug Therapy, Combination | 3 | 2020 | 894 | 0.170 |
Why?
|
| Russia | 2 | 2015 | 25 | 0.170 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 1169 | 0.170 |
Why?
|
| Australia | 2 | 2015 | 99 | 0.160 |
Why?
|
| Government Regulation | 1 | 2018 | 49 | 0.160 |
Why?
|
| Diabetes Mellitus | 2 | 2012 | 806 | 0.160 |
Why?
|
| Cell Hypoxia | 1 | 2019 | 164 | 0.160 |
Why?
|
| Oxygen Consumption | 1 | 2019 | 239 | 0.160 |
Why?
|
| Surgeons | 1 | 2022 | 238 | 0.160 |
Why?
|
| Acid Phosphatase | 3 | 2008 | 33 | 0.160 |
Why?
|
| Mice, Inbred Strains | 4 | 2008 | 307 | 0.160 |
Why?
|
| Kidney Function Tests | 1 | 2018 | 123 | 0.160 |
Why?
|
| Risk Assessment | 3 | 2019 | 2261 | 0.150 |
Why?
|
| Case-Control Studies | 4 | 2019 | 1804 | 0.150 |
Why?
|
| Disability Evaluation | 1 | 2018 | 136 | 0.150 |
Why?
|
| Body Weight | 1 | 2018 | 459 | 0.150 |
Why?
|
| Arthritis, Experimental | 1 | 2017 | 24 | 0.150 |
Why?
|
| 24,25-Dihydroxyvitamin D 3 | 1 | 2016 | 2 | 0.150 |
Why?
|
| Granzymes | 1 | 2017 | 93 | 0.150 |
Why?
|
| International Agencies | 1 | 2016 | 34 | 0.150 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2019 | 332 | 0.150 |
Why?
|
| Blood Chemical Analysis | 1 | 2016 | 42 | 0.150 |
Why?
|
| Osteocalcin | 3 | 2001 | 26 | 0.140 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2016 | 22 | 0.140 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 50 | 0.140 |
Why?
|
| Pain Measurement | 1 | 2018 | 321 | 0.140 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2019 | 261 | 0.140 |
Why?
|
| Organ Culture Techniques | 5 | 2000 | 135 | 0.140 |
Why?
|
| Guideline Adherence | 1 | 2018 | 223 | 0.140 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 2705 | 0.140 |
Why?
|
| Immunoassay | 2 | 2016 | 92 | 0.140 |
Why?
|
| Extracorporeal Circulation | 2 | 2013 | 26 | 0.140 |
Why?
|
| Rats | 11 | 2020 | 3990 | 0.140 |
Why?
|
| Logistic Models | 2 | 2020 | 1185 | 0.140 |
Why?
|
| Vascular Calcification | 1 | 2016 | 39 | 0.130 |
Why?
|
| Blood Glucose | 2 | 2018 | 873 | 0.130 |
Why?
|
| Collagen Type I | 1 | 2015 | 62 | 0.130 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2017 | 166 | 0.130 |
Why?
|
| Organ Transplantation | 1 | 1999 | 265 | 0.130 |
Why?
|
| Incidence | 2 | 2014 | 1576 | 0.130 |
Why?
|
| Prostaglandins | 1 | 1995 | 43 | 0.130 |
Why?
|
| Acidosis, Respiratory | 1 | 1994 | 7 | 0.130 |
Why?
|
| Uremia | 1 | 1994 | 15 | 0.130 |
Why?
|
| Acidosis | 1 | 1994 | 55 | 0.130 |
Why?
|
| Infarction | 1 | 1994 | 26 | 0.130 |
Why?
|
| Sex Factors | 2 | 2013 | 1054 | 0.130 |
Why?
|
| Radiology | 1 | 2017 | 194 | 0.130 |
Why?
|
| Hypocalcemia | 1 | 1994 | 41 | 0.120 |
Why?
|
| Parathyroid Glands | 1 | 1994 | 74 | 0.120 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 364 | 0.120 |
Why?
|
| Sorption Detoxification | 1 | 2013 | 2 | 0.120 |
Why?
|
| Brain Diseases | 1 | 1994 | 180 | 0.110 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 1673 | 0.110 |
Why?
|
| Hematologic Tests | 1 | 2012 | 14 | 0.110 |
Why?
|
| In Vitro Techniques | 3 | 2001 | 989 | 0.110 |
Why?
|
| Colony-Forming Units Assay | 1 | 2012 | 40 | 0.110 |
Why?
|
| Serum | 1 | 2012 | 25 | 0.110 |
Why?
|
| Serum Amyloid P-Component | 1 | 1992 | 5 | 0.110 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2012 | 62 | 0.110 |
Why?
|
| Cell Separation | 1 | 2012 | 196 | 0.110 |
Why?
|
| Phosphate-Binding Proteins | 2 | 2010 | 9 | 0.100 |
Why?
|
| Citric Acid | 2 | 2010 | 38 | 0.100 |
Why?
|
| Cells, Cultured | 4 | 2001 | 2818 | 0.100 |
Why?
|
| Obesity | 1 | 2018 | 963 | 0.100 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 154 | 0.100 |
Why?
|
| Gene Expression | 3 | 2008 | 1284 | 0.100 |
Why?
|
| Wound Healing | 1 | 2013 | 344 | 0.100 |
Why?
|
| Nanocomposites | 1 | 2010 | 11 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2020 | 1219 | 0.100 |
Why?
|
| Absorptiometry, Photon | 3 | 2010 | 99 | 0.100 |
Why?
|
| Deferoxamine | 2 | 1988 | 18 | 0.090 |
Why?
|
| Protein-Energy Malnutrition | 1 | 2010 | 5 | 0.090 |
Why?
|
| Early Diagnosis | 1 | 2010 | 131 | 0.090 |
Why?
|
| Models, Biological | 2 | 2008 | 1749 | 0.090 |
Why?
|
| Bicarbonates | 2 | 2023 | 60 | 0.090 |
Why?
|
| Nervous System Diseases | 1 | 1991 | 151 | 0.090 |
Why?
|
| Global Health | 2 | 2010 | 193 | 0.090 |
Why?
|
| Receptor for Advanced Glycation End Products | 2 | 2013 | 17 | 0.090 |
Why?
|
| Endothelial Cells | 1 | 2012 | 428 | 0.090 |
Why?
|
| Contraindications | 1 | 2009 | 72 | 0.090 |
Why?
|
| Cell Line | 3 | 2013 | 2468 | 0.090 |
Why?
|
| Age Factors | 4 | 2020 | 1849 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2023 | 839 | 0.090 |
Why?
|
| Cell Division | 2 | 2001 | 696 | 0.090 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 3636 | 0.080 |
Why?
|
| Graft Rejection | 2 | 2006 | 1065 | 0.080 |
Why?
|
| Europe | 1 | 2009 | 309 | 0.080 |
Why?
|
| Neuromuscular Diseases | 1 | 1988 | 30 | 0.080 |
Why?
|
| Cross-Over Studies | 1 | 2009 | 399 | 0.080 |
Why?
|
| Tartrate-Resistant Acid Phosphatase | 1 | 2008 | 4 | 0.080 |
Why?
|
| Receptors, Calcitonin | 1 | 2008 | 4 | 0.080 |
Why?
|
| RANK Ligand | 1 | 2008 | 8 | 0.080 |
Why?
|
| Integrin beta3 | 1 | 2008 | 30 | 0.080 |
Why?
|
| Physical Conditioning, Animal | 1 | 2007 | 19 | 0.080 |
Why?
|
| Alzheimer Disease | 2 | 1991 | 470 | 0.080 |
Why?
|
| Cyclic AMP | 2 | 1999 | 273 | 0.080 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2007 | 78 | 0.080 |
Why?
|
| Blood-Brain Barrier | 1 | 2007 | 70 | 0.080 |
Why?
|
| Proteinuria | 1 | 2008 | 107 | 0.080 |
Why?
|
| Placebos | 1 | 2007 | 218 | 0.080 |
Why?
|
| Isoenzymes | 1 | 2008 | 271 | 0.080 |
Why?
|
| Morbidity | 1 | 2007 | 148 | 0.070 |
Why?
|
| Animals, Newborn | 3 | 1994 | 510 | 0.070 |
Why?
|
| Myoclonus | 1 | 1986 | 15 | 0.070 |
Why?
|
| Enzyme Activation | 2 | 1999 | 692 | 0.070 |
Why?
|
| Patient Selection | 1 | 2010 | 685 | 0.070 |
Why?
|
| Microscopy, Electron, Scanning | 2 | 1999 | 135 | 0.070 |
Why?
|
| Regression Analysis | 3 | 2010 | 596 | 0.070 |
Why?
|
| Capsules | 1 | 2006 | 38 | 0.070 |
Why?
|
| Antibodies | 1 | 2008 | 350 | 0.070 |
Why?
|
| Down-Regulation | 2 | 2013 | 504 | 0.070 |
Why?
|
| Adolescent | 3 | 2009 | 8979 | 0.070 |
Why?
|
| Immunosorbent Techniques | 1 | 2005 | 13 | 0.070 |
Why?
|
| Polymers | 2 | 2013 | 202 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2007 | 860 | 0.070 |
Why?
|
| Radius | 1 | 2004 | 29 | 0.060 |
Why?
|
| Patient Satisfaction | 1 | 2008 | 454 | 0.060 |
Why?
|
| Femur Neck | 1 | 2004 | 44 | 0.060 |
Why?
|
| Terminology as Topic | 1 | 2006 | 217 | 0.060 |
Why?
|
| Dementia | 1 | 1986 | 187 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 1990 | 0.060 |
Why?
|
| Postoperative Complications | 2 | 2010 | 2207 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 1 | 2007 | 451 | 0.060 |
Why?
|
| Alkalies | 1 | 2023 | 8 | 0.060 |
Why?
|
| Seizures | 1 | 1986 | 295 | 0.060 |
Why?
|
| Lumbar Vertebrae | 1 | 2004 | 148 | 0.060 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 1 | 2003 | 10 | 0.060 |
Why?
|
| Carpal Tunnel Syndrome | 1 | 2003 | 16 | 0.060 |
Why?
|
| Medical Records | 1 | 2004 | 119 | 0.060 |
Why?
|
| Joints | 1 | 2003 | 32 | 0.060 |
Why?
|
| Membranes, Artificial | 1 | 2003 | 40 | 0.060 |
Why?
|
| Comorbidity | 1 | 2007 | 943 | 0.060 |
Why?
|
| Protein Denaturation | 1 | 2003 | 106 | 0.060 |
Why?
|
| Tacrolimus | 1 | 2004 | 373 | 0.060 |
Why?
|
| Carbon Dioxide | 1 | 2023 | 188 | 0.060 |
Why?
|
| Brain Ischemia | 1 | 2007 | 398 | 0.060 |
Why?
|
| Glucans | 1 | 2002 | 9 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2007 | 469 | 0.050 |
Why?
|
| Osteomalacia | 1 | 2001 | 13 | 0.050 |
Why?
|
| Glucuronidase | 2 | 1992 | 20 | 0.050 |
Why?
|
| Calcitonin | 2 | 1992 | 38 | 0.050 |
Why?
|
| Diuretics, Osmotic | 1 | 2001 | 2 | 0.050 |
Why?
|
| Anthraquinones | 1 | 2001 | 8 | 0.050 |
Why?
|
| Mannitol | 1 | 2001 | 49 | 0.050 |
Why?
|
| Coloring Agents | 1 | 2001 | 64 | 0.050 |
Why?
|
| Tissue Distribution | 2 | 2020 | 290 | 0.050 |
Why?
|
| Kinetics | 2 | 2020 | 1513 | 0.050 |
Why?
|
| Potassium Channels, Calcium-Activated | 1 | 2000 | 19 | 0.050 |
Why?
|
| Sepharose | 2 | 2013 | 14 | 0.050 |
Why?
|
| Vitamin B Complex | 1 | 2020 | 21 | 0.050 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 38 | 0.050 |
Why?
|
| Staurosporine | 1 | 1999 | 33 | 0.050 |
Why?
|
| Rats, Wistar | 1 | 2020 | 297 | 0.040 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2019 | 20 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 2000 | 114 | 0.040 |
Why?
|
| Polyglycolic Acid | 1 | 1999 | 9 | 0.040 |
Why?
|
| Fibrosis | 1 | 2020 | 203 | 0.040 |
Why?
|
| Biopolymers | 1 | 1998 | 26 | 0.040 |
Why?
|
| Liver Transplantation | 2 | 1999 | 1267 | 0.040 |
Why?
|
| Lactic Acid | 1 | 1999 | 90 | 0.040 |
Why?
|
| Monte Carlo Method | 1 | 2019 | 185 | 0.040 |
Why?
|
| Stroke | 1 | 2007 | 965 | 0.040 |
Why?
|
| Pattern Recognition, Automated | 1 | 2019 | 217 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2019 | 118 | 0.040 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 1998 | 126 | 0.040 |
Why?
|
| Hematoma | 1 | 1999 | 104 | 0.040 |
Why?
|
| Rats, Inbred Strains | 2 | 1996 | 312 | 0.040 |
Why?
|
| Renal Circulation | 1 | 2018 | 61 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2007 | 1753 | 0.040 |
Why?
|
| Potassium Channels | 1 | 2000 | 340 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2000 | 352 | 0.040 |
Why?
|
| Spin Labels | 1 | 2018 | 102 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 864 | 0.040 |
Why?
|
| Reference Values | 1 | 2019 | 674 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2018 | 143 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2000 | 1981 | 0.040 |
Why?
|
| Steroids | 1 | 1998 | 177 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 1 | 1998 | 301 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 1999 | 639 | 0.040 |
Why?
|
| Translocation, Genetic | 1 | 1996 | 265 | 0.030 |
Why?
|
| Prostaglandin Antagonists | 1 | 1995 | 7 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2015 | 48 | 0.030 |
Why?
|
| Indomethacin | 1 | 1995 | 59 | 0.030 |
Why?
|
| Acute Kidney Injury | 2 | 1989 | 295 | 0.030 |
Why?
|
| Radiography | 2 | 1998 | 813 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2015 | 73 | 0.030 |
Why?
|
| 3T3 Cells | 1 | 1994 | 94 | 0.030 |
Why?
|
| Culture Media | 1 | 1994 | 147 | 0.030 |
Why?
|
| Ion Transport | 1 | 1994 | 81 | 0.030 |
Why?
|
| Amyloid | 1 | 1995 | 85 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1019 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2018 | 770 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2015 | 128 | 0.030 |
Why?
|
| Patient Dropouts | 1 | 2014 | 28 | 0.030 |
Why?
|
| Adsorption | 1 | 2013 | 54 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2013 | 56 | 0.030 |
Why?
|
| Serum Albumin, Bovine | 1 | 2013 | 45 | 0.030 |
Why?
|
| Sulfones | 1 | 2013 | 43 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2014 | 76 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2016 | 326 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1685 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 421 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2013 | 63 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2019 | 1204 | 0.030 |
Why?
|
| Constipation | 1 | 2014 | 63 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1994 | 493 | 0.030 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 1993 | 34 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 160 | 0.030 |
Why?
|
| Heart Transplantation | 1 | 1999 | 705 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 1993 | 181 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2014 | 147 | 0.030 |
Why?
|
| Cerebrovascular Circulation | 1 | 1994 | 212 | 0.030 |
Why?
|
| Diarrhea | 1 | 2014 | 182 | 0.030 |
Why?
|
| Neurons | 2 | 2000 | 1546 | 0.030 |
Why?
|
| Blood Donors | 1 | 2012 | 26 | 0.030 |
Why?
|
| Equipment Design | 1 | 2013 | 406 | 0.030 |
Why?
|
| Nausea | 1 | 2014 | 175 | 0.030 |
Why?
|
| Hip | 1 | 1992 | 18 | 0.030 |
Why?
|
| Cohort Studies | 1 | 1999 | 2767 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1992 | 244 | 0.030 |
Why?
|
| Shoulder | 1 | 1992 | 42 | 0.030 |
Why?
|
| Behavior, Animal | 2 | 2007 | 373 | 0.030 |
Why?
|
| Chlorides | 2 | 2002 | 103 | 0.030 |
Why?
|
| Lysosomes | 1 | 1992 | 104 | 0.030 |
Why?
|
| Rabbits | 2 | 2010 | 636 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2013 | 751 | 0.030 |
Why?
|
| Hand | 1 | 1992 | 130 | 0.020 |
Why?
|
| Absorption | 2 | 2002 | 25 | 0.020 |
Why?
|
| Implants, Experimental | 1 | 2010 | 16 | 0.020 |
Why?
|
| Durapatite | 1 | 2010 | 28 | 0.020 |
Why?
|
| Materials Testing | 1 | 2010 | 91 | 0.020 |
Why?
|
| Electroencephalography | 1 | 1994 | 707 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 1992 | 460 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 3092 | 0.020 |
Why?
|
| Reimbursement Mechanisms | 1 | 2010 | 40 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 1456 | 0.020 |
Why?
|
| Heart Failure | 1 | 2019 | 1203 | 0.020 |
Why?
|
| DNA | 2 | 1993 | 1294 | 0.020 |
Why?
|
| Biocompatible Materials | 1 | 2010 | 193 | 0.020 |
Why?
|
| Body Burden | 1 | 1988 | 9 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2010 | 268 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 1990 | 457 | 0.020 |
Why?
|
| Sarcoidosis | 1 | 1988 | 71 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2007 | 17 | 0.020 |
Why?
|
| Collagen Type IV | 1 | 2007 | 24 | 0.020 |
Why?
|
| Proteins | 1 | 1993 | 777 | 0.020 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2007 | 35 | 0.020 |
Why?
|
| Brain Edema | 1 | 2007 | 50 | 0.020 |
Why?
|
| Capillaries | 1 | 2007 | 91 | 0.020 |
Why?
|
| Calcium, Dietary | 1 | 2007 | 63 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2007 | 201 | 0.020 |
Why?
|
| Algorithms | 1 | 2015 | 1830 | 0.020 |
Why?
|
| Medicare | 1 | 2010 | 406 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 916 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2010 | 1538 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2007 | 782 | 0.020 |
Why?
|
| Phenotype | 1 | 2012 | 2377 | 0.020 |
Why?
|
| Fluorides | 1 | 1985 | 13 | 0.020 |
Why?
|
| Receptors, Calcium-Sensing | 1 | 2005 | 14 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 879 | 0.020 |
Why?
|
| Pregnancy Complications | 1 | 1988 | 336 | 0.020 |
Why?
|
| Movement | 1 | 2007 | 299 | 0.020 |
Why?
|
| Sterilization | 1 | 2005 | 7 | 0.020 |
Why?
|
| Drug Stability | 1 | 2005 | 48 | 0.020 |
Why?
|
| Cardiac Surgical Procedures | 1 | 1989 | 462 | 0.020 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2005 | 109 | 0.020 |
Why?
|
| RNA | 1 | 2007 | 560 | 0.010 |
Why?
|
| Titrimetry | 1 | 2003 | 15 | 0.010 |
Why?
|
| Blood | 1 | 2002 | 69 | 0.010 |
Why?
|
| Peritoneum | 1 | 2002 | 57 | 0.010 |
Why?
|
| Aluminum Compounds | 1 | 1982 | 6 | 0.010 |
Why?
|
| Urine | 1 | 2002 | 90 | 0.010 |
Why?
|
| Sodium | 1 | 2002 | 341 | 0.010 |
Why?
|
| Charybdotoxin | 1 | 2000 | 8 | 0.010 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channel beta Subunits | 1 | 2000 | 5 | 0.010 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2000 | 8 | 0.010 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channels | 1 | 2000 | 11 | 0.010 |
Why?
|
| Young Adult | 1 | 2012 | 5974 | 0.010 |
Why?
|
| Haplorhini | 1 | 2000 | 81 | 0.010 |
Why?
|
| Protein Structure, Quaternary | 1 | 2000 | 99 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2000 | 307 | 0.010 |
Why?
|
| Epitopes | 1 | 2000 | 255 | 0.010 |
Why?
|
| Electrophysiology | 1 | 2000 | 401 | 0.010 |
Why?
|
| Maternal-Fetal Exchange | 1 | 1979 | 76 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2000 | 646 | 0.010 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 1998 | 37 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 2000 | 435 | 0.010 |
Why?
|
| Choristoma | 1 | 1998 | 68 | 0.010 |
Why?
|
| Drug Carriers | 1 | 1998 | 81 | 0.010 |
Why?
|
| Prostheses and Implants | 1 | 1998 | 121 | 0.010 |
Why?
|
| Fetus | 1 | 1979 | 226 | 0.010 |
Why?
|
| Ion Channel Gating | 1 | 2000 | 324 | 0.010 |
Why?
|
| Insulin | 1 | 2002 | 1160 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2000 | 853 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1998 | 1014 | 0.010 |
Why?
|
| Peptides | 1 | 2000 | 639 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2000 | 2062 | 0.010 |
Why?
|
| Cations, Monovalent | 1 | 1995 | 6 | 0.010 |
Why?
|
| Cations, Divalent | 1 | 1995 | 39 | 0.010 |
Why?
|
| Surface Properties | 1 | 1995 | 130 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 1998 | 857 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1998 | 996 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2000 | 3030 | 0.010 |
Why?
|
| Platelet Transfusion | 1 | 1995 | 14 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 1995 | 188 | 0.010 |
Why?
|
| Transfusion Reaction | 1 | 1995 | 15 | 0.010 |
Why?
|
| Citrates | 1 | 1995 | 28 | 0.010 |
Why?
|
| Intraoperative Care | 1 | 1995 | 82 | 0.010 |
Why?
|
| Erythrocyte Transfusion | 1 | 1995 | 60 | 0.010 |
Why?
|
| Prevalence | 1 | 1998 | 1239 | 0.010 |
Why?
|
| Water Supply | 2 | 1985 | 60 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1995 | 912 | 0.010 |
Why?
|
| Child | 1 | 2004 | 6926 | 0.010 |
Why?
|
| Anticoagulants | 1 | 1995 | 408 | 0.010 |
Why?
|
| Discriminant Analysis | 1 | 1989 | 66 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1995 | 2378 | 0.010 |
Why?
|
| Pregnancy Trimester, Second | 1 | 1988 | 66 | 0.010 |
Why?
|
| Pregnancy | 2 | 1988 | 2893 | 0.000 |
Why?
|
| Computers | 1 | 1985 | 112 | 0.000 |
Why?
|
| Binding Sites | 1 | 1985 | 1098 | 0.000 |
Why?
|
| Brain | 2 | 1985 | 2216 | 0.000 |
Why?
|
| Avoidance Learning | 1 | 1982 | 16 | 0.000 |
Why?
|
| Extinction, Psychological | 1 | 1982 | 19 | 0.000 |
Why?
|
| Rats, Inbred F344 | 1 | 1982 | 156 | 0.000 |
Why?
|
| Michigan | 1 | 1981 | 52 | 0.000 |
Why?
|
| Motor Skills | 1 | 1982 | 71 | 0.000 |
Why?
|
| Brain Chemistry | 1 | 1981 | 121 | 0.000 |
Why?
|
| Dogs | 1 | 1981 | 685 | 0.000 |
Why?
|
| Motor Activity | 1 | 1982 | 327 | 0.000 |
Why?
|
| Teratogens | 1 | 1979 | 13 | 0.000 |
Why?
|
| Fetal Death | 1 | 1979 | 56 | 0.000 |
Why?
|
| Drug Synergism | 1 | 1979 | 303 | 0.000 |
Why?
|
| Neutron Activation Analysis | 1 | 1978 | 2 | 0.000 |
Why?
|
| Spectrophotometry, Atomic | 1 | 1978 | 12 | 0.000 |
Why?
|
| Gestational Age | 1 | 1979 | 311 | 0.000 |
Why?
|
| Mental Disorders | 1 | 1978 | 371 | 0.000 |
Why?
|